Literature DB >> 20564612

Generation of stable cell clones expressing mixtures of human antibodies.

John de Kruif1, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therèse Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, Ton Logtenberg.   

Abstract

Therapeutic monoclonal antibodies, a highly successful class of biological drugs, are conventionally manufactured in mammalian cell lines. A recent approach to increase the therapeutic effectiveness of monoclonal antibodies has been to combine two or more of them; however this increases the complexity of development and manufacture. To address this issue a method to efficiently express multiple monoclonal antibodies from a single cell has been developed and we describe here the generation of stable cell clones that express high levels of a human monoclonal antibody mixture. PER.C6 cells were transfected with a combination of plasmids containing genes encoding three different antibodies. Clones that express the three corresponding antibody specificities were identified, subcloned, and passaged in the absence of antibiotic selection pressure. At several time points, batch production runs were analyzed for stable growth and IgG production characteristics. The majority (11/12) of subclones analyzed expressed all three antibody specificities in constant ratios with total IgG productivity ranging between 15 and 20 pg/cell/day under suboptimal culture conditions after up to 67 population doublings. The growth and IgG production characteristics of the stable clones reported here resemble those of single monoclonal antibody cell lines from conventional clone generation programs. We conclude that the methodology described here is applicable to the generation of stable PER.C6(R) clones for industrial scale production of mixtures of antibodies. (c) 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564612     DOI: 10.1002/bit.22763

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  10 in total

1.  Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry.

Authors:  Natalie J Thompson; Linda J A Hendriks; John de Kruif; Mark Throsby; Albert J R Heck
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 2.  Oligoclonal antibodies to target the ErbB family.

Authors:  Jimson W D'Souza; Matthew K Robinson
Journal:  Expert Opin Biol Ther       Date:  2015-05-02       Impact factor: 4.388

3.  Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics.

Authors:  Gwendolyn M Wilmes; Kimberly L Carey; Stuart W Hicks; Hugh H Russell; Jesse A Stevenson; Paulina Kocjan; Stephen R Lutz; Rachel S Quesenberry; Sergey V Shulga-Morskoy; Megan E Lewis; Ethan Clark; Violetta Medik; Anthony B Cooper; Elizabeth E Reczek
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

4.  A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line.

Authors:  Jie Yu; Xiaoxiao Wang; Tao Xu; Qiuheng Jin; Jinyuan Duan; Jie Wu; Haiyan Wu; Ting Xu; Sheng Ye
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

5.  A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1.

Authors:  Camilla De Nardis; Linda J A Hendriks; Emilie Poirier; Tudor Arvinte; Piet Gros; Alexander B H Bakker; John de Kruif
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

6.  IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.

Authors:  Peter-Christian Klöhn; Ulrich Wuellner; Nora Zizlsperger; Yu Zhou; Daniel Tavares; Sven Berger; Kirstin A Zettlitz; Gabriele Proetzel; May Yong; Richard H J Begent; Janice M Reichert
Journal:  MAbs       Date:  2013 Mar-Apr       Impact factor: 5.857

7.  Back to the future: recombinant polyclonal antibody therapeutics.

Authors:  Xian-Zhe Wang; Vincent W Coljee; Jennifer A Maynard
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

8.  Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?

Authors:  Andreas H Laustsen; Kristoffer H Johansen; Mikael Engmark; Mikael R Andersen
Journal:  PLoS Negl Trop Dis       Date:  2017-02-03

Review 9.  Advances in recombinant antibody manufacturing.

Authors:  Renate Kunert; David Reinhart
Journal:  Appl Microbiol Biotechnol       Date:  2016-03-03       Impact factor: 4.813

Review 10.  Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.

Authors:  Davide Corti; Jeffrey D Kearns
Journal:  Curr Opin Immunol       Date:  2016-03-23       Impact factor: 7.486

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.